Skip to main content
TipRanks
Go Ultimate75% OFF

Ensysce Biosciences (ENSC) Ratios

323 Followers

Ensysce Biosciences Ratios

ENSC's free cash flow for Q3 2026 was $-1.45M. For the 2026 fiscal year, ENSC's free cash flow was decreased by $-51.75K and operating cash flow was $-1.40M. See a summary of the company’s cash flow.

Financial ratios
RatiosDec 25Dec 24Dec 23Dec 22Mar 22
Liquidity Ratios
Current Ratio1.592.420.690.560.95
Quick Ratio1.592.420.690.560.98
Cash Ratio0.941.590.340.330.74
Solvency Ratio-2.23-3.60-3.16-2.44-1.18
Operating Cash Flow Ratio-1.71-3399198.17-3.23-1.89-0.50
Short-Term Operating Cash Flow Coverage-25.45-24871378.37-12.61-4.19-0.65
Net Current Asset Value$ 2.67M$ 3.13M$ -1.07M$ -4.62M$ -8.91M
Leverage Ratios
Debt-to-Assets Ratio0.040.050.320.751.05
Debt-to-Equity Ratio0.100.08-2.65-1.19-2.19
Debt-to-Capital Ratio0.090.081.616.161.84
Long-Term Debt-to-Capital Ratio0.000.000.00-0.04-1.29
Financial Leverage Ratio2.321.51-8.39-1.58-2.08
Debt Service Coverage Ratio-31.19-4.23-8.87-5.54-1.85
Interest Coverage Ratio-545.69-5.22-30.28-221.16-15.34
Debt to Market Cap0.130.020.020.180.01
Interest Debt Per Share0.130.910.5325.25220.30
Net Debt to EBITDA0.390.480.03-0.05-0.19
Profitability Margins
Gross Profit Margin-104.81%-38.57%-240.12%-686.08%100.00%
EBIT Margin-200.48%-129.17%-480.41%-959.91%-734.32%
EBITDA Margin-200.35%-129.17%-480.41%-959.90%-734.32%
Operating Profit Margin-202.12%-129.17%-480.41%-959.91%-562.71%
Pretax Profit Margin-200.85%-153.30%-476.29%-959.33%-825.38%
Net Profit Margin-200.84%-153.30%-475.71%-957.93%-823.62%
Continuous Operations Profit Margin-200.85%-153.30%-476.29%-959.33%-825.38%
Net Income Per EBT100.00%100.00%99.88%99.85%99.79%
EBT Per EBIT99.37%118.68%99.14%99.94%146.68%
Return on Assets (ROA)-136.54%-142.70%-391.90%-410.74%-177.15%
Return on Equity (ROE)-316.63%-215.37%3287.20%650.76%369.16%
Return on Capital Employed (ROCE)-355.00%-198.52%1715.21%676.75%30894.52%
Return on Invested Capital (ROIC)-320.89%-182.30%-4663.69%-3388.81%-156.35%
Return on Tangible Assets-136.54%-142.70%-391.90%-410.74%-177.15%
Earnings Yield-432.56%-56.17%-29.48%-99.51%-2.05%
Efficiency Ratios
Receivables Turnover12.0541.9822.879.127.99
Payables Turnover3.185.323.926.740.00
Inventory Turnover0.000.000.000.00-0.00
Fixed Asset Turnover40.820.000.000.000.00
Asset Turnover0.680.930.820.430.22
Working Capital Turnover Ratio1.744.98-0.86-1.01-0.94
Cash Conversion Cycle-84.65-59.92-77.18-14.13-1795524.71
Days of Sales Outstanding30.288.7015.9640.0445.66
Days of Inventory Outstanding0.000.000.000.00-1067736.19
Days of Payables Outstanding114.9468.6293.1454.17727834.17
Operating Cycle30.288.7015.9640.04-1067690.53
Cash Flow Ratios
Operating Cash Flow Per Share-3.05-4294619.35-4.76-99.41-98.10
Free Cash Flow Per Share-3.10-4294619.35-4.76-99.41-98.10
Dividend Paid and CapEx Coverage Ratio-63.14-25871.380.000.000.00
Capital Expenditure Coverage Ratio-63.140.000.000.000.00
Operating Cash Flow Coverage Ratio-25.45-24871378.37-12.61-4.03-0.48
Operating Cash Flow to Sales Ratio-1.54-1440057.58-4.83-7.09-2.33
Free Cash Flow Yield-337.09%-52759451.44%-29.95%-73.64%-0.58%
Valuation Ratios
Price-to-Earnings (P/E) Ratio-0.23-1.78-3.39-1.00-48.88
Price-to-Sales (P/S) Ratio0.462.7316.149.63402.58
Price-to-Book (P/B) Ratio0.733.83-111.50-6.54-180.44
Price-to-Free Cash Flow (P/FCF) Ratio-0.30-0.00-3.34-1.36-172.48
Price-to-Operating Cash Flow Ratio-0.30-0.00-3.34-1.36-172.48
Price-to-Earnings Growth (PEG) Ratio0.020.700.040.020.00
Enterprise Value Multiple0.16-1.64-3.33-1.06-55.01
Enterprise Value-1.65M11.02M35.73M25.58M1.43B
EV to EBITDA0.16-1.64-3.33-1.06-55.01
EV to Sales-0.332.1216.0110.14403.98
EV to Free Cash Flow0.21-0.00-3.31-1.43-173.08
EV to Operating Cash Flow0.21-0.00-3.31-1.43-173.08
Tangible Book Value Per Share1.131.93-0.29-22.40-97.10
Shareholders’ Equity Per Share1.262.12-0.14-20.64-93.77
Tax and Other Ratios
Effective Tax Rate0.000.000.000.000.00
Revenue Per Share1.982.980.9914.0242.03
Net Income Per Share-3.98-4.57-4.69-134.34-346.16
Tax Burden1.001.001.001.001.00
Interest Burden1.001.190.991.001.12
Research & Development to Revenue2.051.393.407.861.33
SG&A to Revenue0.970.912.402.740.00
Stock-Based Compensation to Revenue0.0321252.020.390.420.03
Income Quality0.77939362.911.010.740.28

Currency in USD